Media Newsroom of

Aalto Bio Reagents Ltd

Church Lane,
Rathfarnham Village, Dublin D14 RK22
Aalto Bio Reagents Ltd

Aalto Bio Reagents Ltd is one of the longest, established, privately-held biotech companies, founded in 1978, and is a leading global provider of high-quality raw materials to the in-vitro diagnostic industry and research laboratories.

Aalto Bio Reagents Launches First nCOV Nucleocapsid Based Monoclonal Antibody for Antigen Testing for COVID 19

Aalto Bio Reagents Launches First nCOV Nucleocapsid Based Monoclonal Antibody for Antigen Testing for COVID 19

Aalto Bio Reagents has just announced the availability of its first mouse monoclonal antibody against SARS-CoV-2 nucleocapsid protein (code CA 1360), which they expect will be a game changer globally. These 5 clones were developed for use in a variety…

Aalto Bio Reagents announces it is supplying reagents for the manufacturing of tens of millions of COVID-19 antibody tests per month

Aalto Bio Reagents announces it is supplying reagents for the manufacturing of tens of millions of COVID-19 antibody tests per month

Aalto Bio Reagents Ltd. a leading developer of critical raw materials and reagents for the development of diagnostic tests, globally announced today that its Sars-CoV-2 n-s1-S2 antigens, Lysis buffers and Viral transport media are part of assays that are being…

Aalto Bio Reagents Launches New Recombinant Eukaryotic SARS-CoV-2, S1-S2 Spike Proteins for Improved Diagnostic Testing of COVID-19

Aalto Bio Reagents Launches New Recombinant Eukaryotic SARS-CoV-2, S1-S2 Spike Proteins for Improved Diagnostic Testing of COVID-19

Aalto Bio Reagents today announced the availability of its new range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers and researchers globally. Among all structural proteins of SARS-CoV-2, the S protein is the main antigenic component…

Aalto Bio Reagents Launches rna Lysis Buffer Reagent for Use in Hospitals and Laboratories for COVID-19 Testing

Aalto Bio Reagents Launches rna Lysis Buffer Reagent for Use in Hospitals and Laboratories for COVID-19 Testing

​​​​​Aalto Bio Reagents Ltd., Ireland’s only developer of critical raw materials and reagents for diagnostic tests, today announced the availability of the first rna Lysis buffer reagent for the pre-treatment of COVID-19 samples prior to testing.  Aalto Bio was contacted by the HSE…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login